Table of Contents
Insulin therapy remains one of the most critical interventions in diabetes management, serving as a lifeline for millions of people with type 1 diabetes and an essential treatment option for many with type 2 diabetes. However, the effectiveness of insulin therapy extends far beyond simply prescribing insulin—it requires a sophisticated, individualized approach that considers each patient’s unique physiological characteristics, lifestyle factors, and treatment goals. Personalized care is important as well, meaning directed target ranges and patient-specific insulin dosing. This comprehensive guide explores evidence-based strategies for tailoring insulin therapy to optimize glycemic control, minimize complications, and enhance quality of life for people living with diabetes.
Understanding the Foundation of Personalized Insulin Therapy
The concept of personalized insulin therapy has evolved significantly over the past decade, driven by technological advances and a deeper understanding of diabetes pathophysiology. Effective and personalized treatment strategies are essential for improving patient outcomes and reducing healthcare costs. Machine learning (ML) has the potential to create clinical decision support systems (CDSS) that assist clinicians in making prediction-informed treatment decisions. Modern diabetes care recognizes that no two patients respond identically to insulin, and that factors such as insulin sensitivity, glucose variability, and individual lifestyle patterns must all be considered when designing treatment regimens.
Research has revealed that insulin resistance manifests differently across individuals, influenced by unique molecular and protein profiles. By mapping these individual “insulin fingerprints,” doctors can design therapies that are specific to a patient’s biology, rather than relying on standard medication regimens. This precision medicine approach represents a paradigm shift from the traditional one-size-fits-all model to truly individualized care.
Comprehensive Patient Assessment: The Starting Point
Effective insulin therapy begins with a thorough and multifaceted assessment of the patient. This evaluation should encompass not only clinical parameters but also psychosocial factors that influence diabetes management and treatment adherence.
Clinical Parameters
A comprehensive clinical assessment includes evaluation of current glycemic control through HbA1c testing, fasting and postprandial glucose levels, and patterns of glucose variability. Perform an A1C test on all people with diabetes or hyperglycemia (random blood glucose >140 mg/dL [>7.8 mmol/L]) admitted to the hospital if no A1C test result is available from the prior 3 months. Understanding the patient’s current insulin regimen, if any, and their response to previous treatments provides valuable insights for optimization.
Body weight and composition significantly influence insulin requirements, as insulin sensitivity varies with adiposity and muscle mass. Age-related factors also play a crucial role, with pediatric patients, adolescents, adults, and elderly individuals each presenting unique considerations for insulin dosing and management strategies. Comorbid conditions such as cardiovascular disease, kidney disease, gastroparesis, and other endocrine disorders can substantially impact insulin pharmacokinetics and treatment goals.
Lifestyle and Behavioral Factors
Physical activity patterns profoundly affect insulin sensitivity and glucose utilization. Patients with regular exercise routines may require different basal and bolus insulin doses compared to sedentary individuals. Dietary habits, including meal timing, composition, and consistency, directly influence prandial insulin requirements and must be carefully evaluated.
Work schedules, particularly for shift workers or those with irregular hours, present unique challenges for insulin timing and dosing. Sleep patterns and quality also impact glucose regulation and insulin sensitivity. Stress levels, both acute and chronic, can significantly affect blood glucose through hormonal mechanisms, necessitating adjustments in insulin therapy.
Psychosocial Considerations
Patient motivation, health literacy, and understanding of diabetes management principles are critical factors in successful insulin therapy. Financial resources and insurance coverage affect access to insulin formulations, delivery devices, and monitoring technologies. Social support systems, including family involvement and community resources, can significantly influence treatment adherence and outcomes.
Insulin Types and Pharmacokinetic Profiles
Understanding the pharmacokinetic properties of different insulin formulations is essential for designing effective regimens. Each insulin type has distinct onset, peak, and duration characteristics that must be matched to patient needs.
Rapid-Acting Insulin Analogs
Rapid-acting insulin analogs, including insulin lispro, aspart, and glulisine, begin working within 10-15 minutes of injection. The pharmacodynamics of various bolus sizes of the rapid-acting insulin analog, glulisine (same for the other rapid-acting analogs, i.e., lispro and aspart). Note that the peak action occurs nearly 2 h after the bolus. Also note that the more insulin is injected, the later the peak and the longer the duration of action. These insulins are typically administered immediately before or with meals to cover postprandial glucose excursions.
The FDA’s approval of insulin aspart-xjhz as an interchangeable biosimilar to NovoLog improves affordability and access to rapid-acting insulin. The availability of biosimilar options has expanded access to these essential medications, potentially reducing cost barriers for many patients.
Short-Acting (Regular) Insulin
Regular human insulin has a slower onset (30-60 minutes) and longer duration of action compared to rapid-acting analogs. While less commonly used in modern intensive insulin regimens, regular insulin may be appropriate for certain patients, particularly those with gastroparesis or when a more prolonged prandial insulin effect is desired.
Intermediate-Acting Insulin
NPH (Neutral Protamine Hagedorn) insulin provides intermediate-duration coverage, typically lasting 12-18 hours with a pronounced peak effect. While largely replaced by long-acting analogs in many treatment regimens, NPH remains a cost-effective option and may be useful in specific clinical scenarios or resource-limited settings.
Long-Acting Basal Insulin Analogs
Long-acting insulin analogs, including insulin glargine, detemir, and degludec, provide relatively peakless basal insulin coverage for 18-42 hours depending on the formulation. These insulins form the foundation of most modern insulin regimens, mimicking physiologic basal insulin secretion and providing stable background glucose control.
Ultra-Long-Acting and Novel Formulations
Once-weekly insulin efsitora alfa offers noninferior glucose control compared to daily insulins, reducing the injection burden and potentially enhancing adherence. This emerging class of insulin represents a significant advancement in convenience and may improve adherence for patients who struggle with daily injections. Across the QWINT program, efsitora demonstrated similar reductions in HbA1c and comparable safety profiles, with some trials showing a 1.31% reduction over 52 weeks. By reducing the treatment burden from 365 injections per year to just 52, this once-weekly regimen aims to simplify therapy and reduce the clinical inertia often associated with starting insulin for type 2 diabetes.
Insulin Dosing Strategies and Regimens
Selecting the appropriate insulin regimen requires careful consideration of the patient’s diabetes type, glycemic control goals, lifestyle factors, and ability to manage complex dosing schedules.
Basal Insulin Therapy
Basal insulin provides background insulin coverage to suppress hepatic glucose production and maintain glucose levels between meals and overnight. Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This is called background or basal insulin replacement. The basal or background insulin dose usually is constant from day to day. For patients with type 2 diabetes, basal insulin alone may be sufficient initially, particularly when combined with oral antidiabetic medications.
The mainstay of treatment for those with adequate nutrition remains basal insulin with scheduled mealtime (bolus) insulin. This basal-bolus approach more closely mimics physiologic insulin secretion and provides superior glycemic control compared to basal insulin alone in many patients.
Prandial (Bolus) Insulin Dosing
Prandial insulin covers the glucose excursion associated with meals and snacks. Many people with diabetes dose their mealtime insulin based on two factors: the carbohydrates in the food they are about to eat (using their I:C ratio) and their need for correctional insulin to bring their current premeal glucose level into the target range (based on an individualized insulin sensitivity factor [ISF], which is the blood glucose lowering in mg/dL to be expected per unit of rapid-acting insulin delivered when glucose is above target).
The insulin to carbohydrate ratio represents how many grams of carbohydrate are covered or disposed of by 1 unit of insulin. Generally, one unit of rapid-acting insulin will dispose of 12-15 grams of carbohydrate. However, this ratio varies considerably among individuals and may differ at different times of day for the same person.
Correction (Supplemental) Insulin
Correction insulin addresses elevated glucose levels outside of meal times. The bolus dose for high blood glucose correction is defined as how much one unit of rapid-acting insulin will drop the blood glucose. Generally, to correct a high blood glucose, one unit of insulin is needed to drop the blood glucose by 50 mg/dl. Individual correction factors must be determined through careful monitoring and adjustment.
For most individuals, sole use of a correction or supplemental insulin without basal insulin (formerly referred to as a sliding scale) in the inpatient setting is discouraged. This outdated approach fails to provide adequate basal coverage and often results in suboptimal glycemic control.
Simplified Dosing Algorithms
This novel approach requires neither carbohydrate counting nor postmeal glucose testing. Throughout the week, patients use the premeal and bedtime blood glucose values and meal size to adjust doses at each meal. For patients who find carbohydrate counting challenging, simplified algorithms based on meal size and premeal glucose values can provide effective glycemic control while reducing treatment complexity.
The algorithm follows a simple, systematic approach that facilitates simultaneous daily mealtime insulin adjustments with weekly adjustments of both mealtime and basal insulin doses. This approach maintains balance between basal and bolus insulin, reducing the risk of over-insulinization and hypoglycemia.
Advanced Insulin Delivery Systems
Technological advances have revolutionized insulin delivery, offering patients unprecedented precision and convenience in diabetes management.
Insulin Pumps and Continuous Subcutaneous Insulin Infusion
Insulin pumps deliver rapid-acting insulin continuously through a subcutaneous catheter, providing precise basal rates that can be programmed to vary throughout the day. This flexibility allows for optimization of basal insulin delivery to match individual circadian patterns of insulin sensitivity. Pumps also facilitate precise bolus dosing with increments as small as 0.025 units, enabling fine-tuning of prandial insulin doses.
Automated Insulin Delivery (AID) Systems
Automated insulin delivery (AID) systems have revolutionized type 1 diabetes management, offering improved glycemic control, reduced hypoglycemia, and enhanced quality of life for diverse patient populations. Continuous advances and accumulated real-world evidence support the expansion of AID use to previously excluded groups, including those with challenging glycemic profiles, pregnant women, and young children.
Artificial pancreas systems, which integrate CGM with automated insulin delivery, have shown significant efficacy in maintaining glycemic control by dynamically adjusting insulin doses based on real-time glucose data. These systems represent the closest approximation to physiologic insulin secretion currently available, automatically adjusting insulin delivery in response to changing glucose levels.
Optional meal bolusing allows the system to bolus each meal automatically or users may choose to bolus using a simple meal announcement or a traditional carb announcement. Revolutionized hourly adaptation and personalization of insulin deliveries. Next-generation AID systems are moving toward full automation, reducing the burden of diabetes management while maintaining excellent glycemic control.
These challenges are now catalyzing development of next-generation AID technologies with a focus on achieving full automation, greater personalization, and broader accessibility. This review examines key limitations of current AID systems and explores future directions, including fully closed-loop control, novel insulin formulations, multi-hormonal systems, advanced sensor technologies, and integration of wearable and artificial intelligence tools.
Smart Insulin Pens
For individuals who require intensive insulin therapy but do not wish to use an insulin pump, advances in insulin pens allow them to continue on injection therapy with “connected” insulin pens that offer connectivity with CGM and some BGM meters, built-in memory, and download capability. These devices bridge the gap between traditional injection therapy and pump therapy, providing many of the benefits of connected diabetes technology without requiring a pump.
Real-world data from the BURST study, also presented at the 2025 ADA 85th Scientific Sessions, demonstrated that the Bigfoot Unity Diabetes Management System significantly improves long-term outcomes for patients on multiple daily injections. By integrating a smart insulin pen cap with continuous glucose monitor data, the system provides real-time dose recommendations and alerts for missed doses, which led to a 1.3% mean reduction in HbA1c over 12 months among participants.
Continuous Glucose Monitoring: The Game Changer
Continuous glucose monitoring has fundamentally transformed diabetes management, providing unprecedented insight into glucose patterns and enabling more precise insulin dosing decisions.
CGM Technology and Capabilities
In the late 1990s, continuous glucose monitoring (CGM) was developed. Providing 288 glucose readings per day, it revealed that neither self-monitoring of blood glucose (SMBG) nor HbA1c reflected the postmeal and glucose swings during sleep. This continuous data stream provides a complete picture of glycemic patterns that was previously impossible to obtain.
Continuous glucose monitoring (CGM) measures interstitial glucose every 5 min, thus providing a more complete glycemic profile during a 24 h period compared with standard POC glucose testing. This granular data enables identification of patterns and trends that inform insulin dose adjustments and lifestyle modifications.
Expanded Indications for CGM Use
In particular, hosts pointed to stronger ADA recommendations for CGM use, including for individuals with type 2 diabetes (T2D) not on insulin therapy, and emphasized the importance of CGM for all patients on insulin therapy to reduce hypoglycemia risks. The 2025 ADA Standards of Care reflect growing evidence supporting broader CGM use across diverse patient populations.
Emerging evidence supports CGM as a transformative tool for non-insulin-treated T2D. Clinical studies demonstrate CGM’s association with improved glycemic control, reduced hypoglycemia risk, and enhanced healthcare efficiency. Even patients not using insulin can benefit from the insights provided by CGM data to guide lifestyle modifications and medication adjustments.
Using CGM Data for Insulin Adjustments
Moreover, because rtCGM provides continuous feedback (eg, alerts, trending and current glucose data), the user has the ability to “fine-tune” treatment as needed and make any follow-up adjustments if the dose given was too high or too low. Real-time CGM enables dynamic insulin dosing decisions based on current glucose levels and rate of change.
Trend arrows may be used to make insulin dose adjustments for CGM users who are prescribed bolus insulin. The directional arrows displayed on CGM devices indicate the rate and direction of glucose change, allowing users to adjust insulin doses proactively to prevent hyper- or hypoglycemia.
Although accurate prediction of an exact glucose level at any future time is unrealistic, the anticipated 30-minute glucose range indicated by the ROC arrows provides a narrow enough estimate to make appropriate treatment decisions. This predictive capability enables preemptive insulin dose adjustments that improve glycemic outcomes.
Important Considerations for CGM Use
However, users should be cautioned about stacking their doses (taking multiple boluses too close together in time). If a user gives a correction dose within 2 hours of the last bolus, the risk of hypoglycemia is increased because subcutaneously delivered rapid-acting insulin can take up to 90-120 minutes to peak and may still be working 4 to 5 hours after the injection. Understanding insulin pharmacokinetics remains essential even with advanced monitoring technology.
We do not advise patients to immediately begin following these recommendations until they are comfortable with the device and feel that the results accurately match their SMBG results. Once they gain confidence in their rtCGM data, they can begin using the information to make treatment decisions. A gradual learning curve ensures safe and effective CGM utilization.
Monitoring Strategies and Insulin Dose Optimization
Effective insulin therapy requires systematic monitoring and regular dose adjustments based on comprehensive data analysis.
Key Glycemic Metrics
Time in range (TIR), defined as the percentage of time glucose levels remain between 70-180 mg/dL, has emerged as a critical metric for assessing glycemic control. TIR correlates strongly with long-term complications and provides more actionable information than HbA1c alone. Time below range (TBR) quantifies hypoglycemia exposure, with targets of less than 4% for glucose below 70 mg/dL and less than 1% for glucose below 54 mg/dL. Time above range (TAR) indicates hyperglycemia burden and guides intensification of therapy.
Glucose variability, measured by coefficient of variation (CV), reflects the stability of glucose control. A CV below 36% indicates stable glucose levels, while higher values suggest excessive variability requiring intervention. Mean glucose provides an overall assessment of glycemic control and correlates with HbA1c, though it doesn’t capture the nuances of glucose patterns.
Structured Approach to Insulin Dose Adjustments
In order to determine these dosing factors accurately, one eliminates variation caused by variable food intake and insufficient number of glucose measurements. Systematic data collection and analysis are essential for making appropriate insulin dose adjustments.
TBD, ICR, and CF are reflective of insulin sensitivity; so, it is not surprising that they are all mathematically related. When adjusting or setting dosing parameters, consider these mathematical relationships. They provide an anchor to guide change. Understanding the relationships between total daily dose, insulin-to-carbohydrate ratios, and correction factors helps ensure internally consistent insulin regimens.
In order not to overestimate the insulin dose, we use a conservative approach to the analytics in CGM adjustments. The formulas to be presented will tend to underestimate the dosing parameter change. A cautious approach to dose adjustments minimizes the risk of hypoglycemia while still achieving glycemic targets.
Frequency and Timing of Adjustments
Basal insulin adjustments should typically be made no more frequently than every 2-3 days to allow adequate time to assess the effect of changes. Prandial insulin ratios may require more frequent adjustment, particularly when dietary patterns change or during periods of illness or stress. Correction factors should be evaluated regularly and adjusted based on observed glucose responses to correction doses.
Dose adjustments often are not done in response to BGs out of target. For instance, one study showed that following a hypoglycemia event, physicians adjusted basal insulin only 25% of the time. Proactive and consistent dose adjustments are essential for optimal glycemic control and prevention of recurrent hypo- or hyperglycemia.
Special Considerations in Insulin Therapy
Exercise and Physical Activity
Physical activity increases insulin sensitivity and glucose utilization, often requiring reductions in insulin doses or increased carbohydrate intake to prevent hypoglycemia. The timing, intensity, and duration of exercise all influence glucose responses. Aerobic exercise typically lowers glucose levels during and after activity, while high-intensity or resistance exercise may initially raise glucose due to counter-regulatory hormone release.
Strategies for managing insulin during exercise include reducing basal insulin rates 1-2 hours before planned activity, decreasing prandial insulin doses for meals preceding exercise, and consuming additional carbohydrates as needed. CGM is particularly valuable during exercise, allowing real-time monitoring of glucose trends and early detection of hypoglycemia.
Illness and Stress
Acute illness typically increases insulin requirements due to stress hormone release and increased insulin resistance. Patients should be educated to monitor glucose more frequently during illness, maintain hydration, and increase insulin doses as needed based on glucose levels. Sick day management protocols should be individualized and reviewed regularly with patients.
Chronic stress can also affect glucose control through sustained elevation of cortisol and other counter-regulatory hormones. Addressing stress through behavioral interventions, adequate sleep, and appropriate medical management may improve insulin sensitivity and glycemic control.
Pregnancy
Isaacs and Bellini also highlighted the role of CGM and AID systems during pregnancy, emphasizing the early initiation of technology to achieve personalized glycemic targets and optimize outcomes. Pregnancy presents unique challenges for insulin therapy, with insulin requirements typically increasing substantially, particularly in the second and third trimesters.
Glycemic targets are more stringent during pregnancy to minimize risks to both mother and fetus. Intensive monitoring and frequent insulin dose adjustments are essential. CGM and AID systems can be particularly valuable during pregnancy, helping achieve tight glycemic control while minimizing hypoglycemia risk.
Pediatric Considerations
Children and adolescents present unique challenges for insulin therapy, including unpredictable eating patterns, variable physical activity, and developmental changes affecting insulin sensitivity. Growth and puberty significantly impact insulin requirements, often necessitating frequent dose adjustments.
Family involvement is crucial in pediatric diabetes management, with age-appropriate transition of diabetes care responsibilities from parents to the child. Technology, including CGM and insulin pumps, can be particularly beneficial in pediatric populations, providing parents with remote monitoring capabilities and reducing the burden of frequent fingerstick testing.
Elderly Patients
Older adults often have multiple comorbidities, polypharmacy, and age-related changes in insulin sensitivity and counter-regulatory responses. Hypoglycemia risk is increased in elderly patients due to impaired awareness, reduced counter-regulatory hormone responses, and potential cognitive impairment affecting diabetes self-management.
Glycemic targets may need to be individualized and less stringent in elderly patients, particularly those with limited life expectancy, significant comorbidities, or high hypoglycemia risk. Simplified insulin regimens may be appropriate to reduce treatment complexity and improve adherence.
The Role of Healthcare Professionals in Insulin Management
Multidisciplinary Team Approach
Updated guidelines emphasize multidisciplinary education, telemonitoring, and individualized follow-up to ensure safety and efficacy. Optimal insulin therapy requires collaboration among endocrinologists, primary care physicians, diabetes educators, dietitians, pharmacists, and other healthcare professionals.
Each team member brings unique expertise: physicians provide medical oversight and prescribe insulin regimens, diabetes educators teach insulin administration techniques and self-management skills, dietitians help patients understand carbohydrate counting and meal planning, and pharmacists ensure appropriate insulin storage and address medication access issues.
Certified Diabetes Care and Education Specialists
The CDCES lead protocol proved safe and effective for insulin dosing. We describe the CDCES policy to make incremental dose adjustments and report its safety and effectiveness, which facilitated patients’ reaching and maintaining targets. Expanding the role of certified diabetes educators to include insulin dose adjustments can improve access to timely care and enhance glycemic outcomes.
It is standard practice for CDCES to teach youth with diabetes and their family/caregivers to safely manage and adjust their own insulin doses. We assert that these data provide strong support for CDCESs to safely make dose adjustments following a standardized protocol that can be replicated in other Pediatric diabetes clinics. Empowering diabetes educators to make insulin adjustments within established protocols can increase the frequency of dose optimization and improve patient outcomes.
Telemedicine and Remote Monitoring
CDCESs made insulin dose adjustments and consulted with Pediatric Endocrinologists per protocol and as needed. CDCES sent messages with suggested dose adjustments and behavior changes via secure portal messaging. Remote monitoring and telemedicine have become increasingly important tools for insulin management, particularly in the era of connected diabetes devices.
CGM data sharing allows healthcare providers to review glucose patterns remotely and make timely insulin dose adjustments without requiring in-person visits. This approach can improve access to care, particularly for patients in rural areas or those with transportation challenges. Secure messaging platforms facilitate communication between patients and providers, enabling rapid responses to questions and concerns.
Patient Education and Empowerment
Comprehensive patient education is the cornerstone of successful insulin therapy. Patients must understand not only the technical aspects of insulin administration but also the principles underlying insulin dosing decisions.
Insulin Administration Techniques
Proper injection technique is essential for consistent insulin absorption and optimal glycemic control. Patients should be taught to rotate injection sites systematically to prevent lipohypertrophy, which can impair insulin absorption. Injection angle and depth should be appropriate for the patient’s body habitus, typically using a 90-degree angle for most adults and a 45-degree angle for thin individuals or children.
Insulin storage is critical for maintaining potency. Unopened insulin should be refrigerated, while in-use vials or pens can be kept at room temperature for the duration specified by the manufacturer, typically 28-42 days. Patients should be educated to inspect insulin for changes in appearance and to discard insulin that has been frozen, exposed to extreme heat, or appears cloudy (for clear insulins) or clumped (for cloudy insulins).
Recognizing and Managing Hypoglycemia
Hypoglycemia is the most common acute complication of insulin therapy and a major barrier to achieving optimal glycemic control. Patients must be able to recognize symptoms of hypoglycemia, which may include shakiness, sweating, confusion, irritability, rapid heartbeat, and hunger. However, some patients develop hypoglycemia unawareness, losing the ability to perceive early warning symptoms.
The “rule of 15” provides a simple approach to treating mild to moderate hypoglycemia: consume 15 grams of fast-acting carbohydrate, wait 15 minutes, recheck glucose, and repeat if still low. Patients and family members should be trained in glucagon administration for severe hypoglycemia when the patient is unable to consume oral carbohydrates. Newer glucagon formulations, including nasal and auto-injector devices, have simplified emergency treatment.
Carbohydrate Counting and Meal Planning
For patients using carbohydrate-based insulin dosing, accurate carbohydrate counting is essential. Education should include reading nutrition labels, estimating portion sizes, and understanding the carbohydrate content of common foods. Patients should also learn about the glycemic impact of different foods, as protein and fat can affect postprandial glucose excursions, particularly in large meals.
Meal timing consistency can simplify insulin management, though flexible insulin regimens allow patients to adapt to varying schedules. Patients should understand how to adjust insulin doses for meals of different sizes and compositions, and how to manage special situations such as restaurant meals, parties, and travel.
Sick Day Management
Illness can significantly affect glucose levels and insulin requirements. Patients should be provided with written sick day guidelines that include instructions for monitoring glucose more frequently, maintaining hydration, continuing insulin even if not eating normally, and when to contact their healthcare provider or seek emergency care.
Patients with type 1 diabetes should be educated about diabetic ketoacidosis (DKA) risk during illness and taught to check for ketones when glucose levels are persistently elevated. Clear guidelines for when to seek emergency care should be provided, including persistent vomiting, inability to keep fluids down, moderate to large ketones, or signs of severe dehydration.
Lifestyle Modifications
While insulin therapy is essential for many patients with diabetes, lifestyle modifications remain a critical component of comprehensive diabetes management. Regular physical activity improves insulin sensitivity, aids in weight management, and provides cardiovascular benefits. Patients should be encouraged to engage in at least 150 minutes of moderate-intensity aerobic activity per week, along with resistance training.
Dietary modifications, including a balanced diet rich in vegetables, whole grains, lean proteins, and healthy fats, support glycemic control and overall health. Weight management is particularly important for patients with type 2 diabetes, as even modest weight loss can improve insulin sensitivity and reduce insulin requirements.
Adequate sleep is increasingly recognized as important for glucose regulation, with sleep deprivation associated with increased insulin resistance and impaired glucose tolerance. Stress management techniques, including mindfulness, meditation, and cognitive-behavioral strategies, can help address the psychological burden of diabetes and may improve glycemic control.
Emerging Technologies and Future Directions
Artificial Intelligence and Machine Learning
Artificial intelligence is making a tangible difference in diabetes management. AI-powered wearables can now detect type 2 diabetes risk in real time, analyzing heart rate, activity patterns, and subtle glucose fluctuations. Machine learning is also enhancing insulin management, enabling personalized dosing algorithms that minimize guesswork and optimize blood sugar control.
AI-driven decision support systems are being developed to analyze CGM data, predict glucose trends, and recommend insulin dose adjustments. These systems can identify patterns that may not be apparent to patients or clinicians, potentially improving glycemic outcomes while reducing the cognitive burden of diabetes management.
Fully Closed-Loop Systems
The ultimate goal of automated insulin delivery is a fully closed-loop system that requires no user input for meal announcements or boluses. While current AID systems still require meal announcements for optimal postprandial glucose control, next-generation algorithms are being developed to automatically detect meals and deliver appropriate insulin doses without user intervention.
A notable topic is the ADA’s revised stance on open-source AID systems, explicitly asking clinicians to support and guide patients who use these open-source systems. In particular, the organization recognized its potential to improve outcomes and urged providers to understand the underlying algorithms as they continue to advance. The diabetes community has been at the forefront of innovation, with open-source AID systems demonstrating the potential for advanced automation.
Multi-Hormonal Systems
Research is ongoing into bi-hormonal systems that deliver both insulin and glucagon, potentially providing more physiologic glucose control and reducing hypoglycemia risk. These systems could automatically deliver glucagon to prevent or treat hypoglycemia, eliminating one of the major limitations of current insulin-only AID systems.
Early strategies combined automated insulin delivery with adjunct therapies, such as GLP-1 receptor agonists, SGLT2 inhibitors or pramlintide to improve postprandial glycemic control without prandial insulin boluses. Combination approaches integrating insulin with other glucose-lowering medications may provide synergistic benefits and simplify diabetes management.
Novel Insulin Formulations
Research continues into ultra-rapid-acting insulin formulations that more closely mimic physiologic prandial insulin secretion, potentially improving postprandial glucose control. Glucose-responsive “smart” insulins that automatically activate in response to elevated glucose levels are in development, though significant technical challenges remain before clinical availability.
Alternative delivery routes, including oral and inhaled insulin formulations, continue to be explored as potential alternatives to subcutaneous injection. While inhaled insulin is currently available, its use remains limited due to cost, insurance coverage issues, and concerns about long-term pulmonary effects.
Precision Medicine Approaches
The collective breakthroughs of 2025 emphasize three themes: personalization, prevention, and precision. Tailored interventions: Molecular profiling allows clinicians to target therapies at the individual level. Prevention over reaction: Immunotherapy and early detection strategies reduce disease progression and complications. The future of insulin therapy lies in increasingly personalized approaches based on individual genetic, metabolic, and behavioral profiles.
Biomarkers and genetic testing may eventually guide selection of optimal insulin regimens and predict individual responses to different insulin formulations. Integration of multiple data streams, including CGM, physical activity monitors, sleep trackers, and dietary logs, will enable comprehensive analysis of factors affecting glucose control and more precise insulin dose recommendations.
Overcoming Barriers to Optimal Insulin Therapy
Cost and Access Issues
Insulin affordability remains a critical barrier for many patients, with high out-of-pocket costs leading to insulin rationing and suboptimal glycemic control. Healthcare providers should be aware of patient assistance programs, generic and biosimilar insulin options, and strategies to reduce insulin costs. Advocacy for policy changes to improve insulin affordability and access is essential at both individual and systemic levels.
Access to diabetes technology, including CGM and insulin pumps, is limited by insurance coverage restrictions and high costs. One obstacle with CGMs is the cost of access to diabetes technology. Many people with diabetes who have put off getting an insulin pump or CGM, do so because they are too expensive. Another major obstacle is due to strict Medicaid coverage policies they are not accessible for people who need them. Efforts to expand coverage and reduce costs are needed to ensure equitable access to these beneficial technologies.
Clinical Inertia
Clinical inertia, the failure to initiate or intensify therapy when indicated, is a significant barrier to optimal glycemic control. Healthcare providers may delay insulin initiation or intensification due to concerns about hypoglycemia, treatment complexity, or patient resistance. Systematic approaches to insulin titration, clear protocols for dose adjustments, and regular review of glycemic data can help overcome clinical inertia.
Patient education addressing fears and misconceptions about insulin therapy is essential. Many patients view insulin as a sign of personal failure or fear that starting insulin means their diabetes is “worse.” Reframing insulin as a powerful tool for achieving health goals rather than a punishment can improve acceptance and adherence.
Psychological Barriers
Diabetes distress, depression, and anxiety are common among people with diabetes and can significantly impact diabetes self-management and insulin adherence. Beyond clinical metrics, patients reported a substantial decrease in diabetes distress and an increase in hypoglycemic confidence, suggesting the technology helps simplify complex dosing direction. Screening for psychological issues and providing appropriate referrals for mental health support should be integrated into routine diabetes care.
Fear of hypoglycemia is a major barrier to optimal insulin therapy, often leading patients to maintain glucose levels higher than target to avoid low blood sugar. CGM with predictive alerts can help reduce hypoglycemia fear by providing early warning of impending lows, allowing preventive action before hypoglycemia occurs.
Quality Metrics and Outcomes Assessment
Evaluating the effectiveness of insulin therapy requires assessment of multiple outcomes beyond HbA1c alone. Time in range has emerged as a key metric, with targets of greater than 70% for most adults and greater than 50% for older adults or those with high hypoglycemia risk. Hypoglycemia rates, particularly severe hypoglycemia requiring assistance, should be minimized.
Patient-reported outcomes, including quality of life, treatment satisfaction, and diabetes distress, are increasingly recognized as important measures of treatment success. These metrics capture aspects of the patient experience that may not be reflected in glycemic metrics alone but significantly impact long-term adherence and outcomes.
Healthcare utilization, including emergency department visits and hospitalizations for diabetes-related complications, provides insight into the real-world effectiveness and safety of insulin regimens. Reduction in acute complications and healthcare costs are important goals of optimized insulin therapy.
Practical Implementation Strategies
Successful implementation of personalized insulin therapy requires systematic approaches and clear protocols. Healthcare systems should develop standardized insulin order sets and titration protocols that incorporate evidence-based practices while allowing for individualization. Electronic health record integration of CGM data and insulin dosing calculators can streamline clinical workflows and improve decision-making.
Regular team meetings to review complex cases and discuss challenging management scenarios can enhance provider knowledge and confidence in insulin management. Continuing education programs should keep healthcare professionals updated on new insulin formulations, delivery devices, and management strategies.
Patient registries and quality improvement initiatives can identify gaps in care and track outcomes over time, enabling continuous refinement of insulin management approaches. Sharing best practices across healthcare systems and learning from high-performing centers can accelerate improvement in insulin therapy outcomes.
Conclusion
Tailoring insulin therapy to individual patient needs represents the gold standard in modern diabetes management. By integrating comprehensive patient assessment, appropriate insulin formulations and delivery systems, advanced monitoring technologies, systematic dose optimization, and comprehensive patient education, healthcare providers can help patients achieve optimal glycemic control while minimizing complications and treatment burden.
The rapid pace of technological innovation in diabetes care, including automated insulin delivery systems, continuous glucose monitoring, and artificial intelligence-driven decision support, promises to further improve outcomes and quality of life for people requiring insulin therapy. However, technology alone is not sufficient—successful insulin therapy requires a patient-centered approach that addresses individual needs, preferences, and circumstances.
As we move forward, the focus must remain on personalization, precision, and prevention. By leveraging the full spectrum of available tools and strategies, healthcare providers can help each patient achieve their individual glycemic goals while maintaining safety, minimizing treatment burden, and supporting overall health and well-being. The future of insulin therapy is bright, with continued advances promising even better outcomes for the millions of people worldwide who depend on insulin to manage their diabetes.
Additional Resources
For healthcare professionals and patients seeking additional information on insulin therapy and diabetes management, numerous resources are available. The American Diabetes Association (https://www.diabetes.org) provides comprehensive guidelines, patient education materials, and professional resources. The Endocrine Society offers clinical practice guidelines and educational programs for healthcare providers.
JDRF (https://www.jdrf.org) supports research into type 1 diabetes and provides resources for patients and families. The Diabetes Technology Society (https://www.diabetestechnology.org) focuses on advancing diabetes technology and provides education on CGM, insulin pumps, and automated insulin delivery systems.
Professional organizations including the American Association of Diabetes Educators and the Association of Diabetes Care and Education Specialists offer certification programs and continuing education for diabetes educators and healthcare professionals. These resources, combined with individualized care from knowledgeable healthcare providers, can help patients achieve optimal outcomes with insulin therapy.